|
市場調査レポート
更年期障害治療の機会：新たな治療法はホルモン補充療法を超えるか
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
|
Abstract
Introduction
For decades, the efficacy of hormone replacement therapy (HRT) for some of
menopause' s most troublesome symptoms eliminated any incentive to develop new
approaches to treatment. However, data questioning the safety of
estrogen-containing therapies have galvanized researchers and drug developers
to begin investigating new mechanisms to treat menopausal symptoms that can
capitalize on the newly realized need for safer treatment options, although
these agents will still be challenged by the efficacy of HRTs.
Questions Answered in This Report
- Menopause is a natural process of aging that is accompanied by substantial
hormonal changes. What are the symptoms of menopause? What are the causes of
these symptoms? What are the current treatment options? What are the benefits
and drawbacks of these treatments?
- Data from the Women' s Health Initiative suggest that estrogen therapy is
not suitable for all women. What are the risks associated with hormone
therapy? Do emerging agents offer safer or more efficacious treatment
approaches?
- With the final wave of baby boomers reaching menopausal age, the
menopause treatment patient population is on the rise. What were the sales of
menopausal symptom treatments in 2008? How well will emerging agents address
the remaining needs in this market? How will emerging agents fit into the
treatment algorithm in the future?
Scope
- Overview of menopause: Physiology and symptoms.
- Current treatments: Hormone replacement therapy, selective estrogen
receptor modulators, SSRIs/SNRIs, gabapentin.
- Emerging treatments: Wyeth' s Pristiq, Wyeth' s bazedoxifene/conjugated
estrogens, Depomed' s controlled-release gabapentin, Schering-Plough' s
esmirtazapine.
- Outlook: 2008 market, challenges and opportunities, the potential of
emerging agents, the future of HRT.
- Women' s Health Series: This report is part of Spectrum' s Women' s Health
Series, which focuses on areas of unmet need and the best marketing strategies
to ensure adoption of a new agent into the market for women' s reproductive
health - a sector that exceeded $23 billion in 2007.
Mentioned in This Report
Companies
- Bayer-Schering
- Bionovo
- Boehringer Ingelheim
- Chugai
- Concert Pharmaceuticals
- Depomed
- Eli Lilly
- Forest
- GlaxoSmithKline
- Novartis
- Novo Nordisk
- Pfizer
- Radius
- Schering-Plough
- Solvay
- Wyeth
Table of Contents
Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Overview of Menopause
- Definition and Description
- Symptoms of Menopause
- Vasomotor Symptoms
- Osteoporosis
- Increased Cardiovascular Disease Risk
- Insomnia
- Depression
- Other Symptoms
Current Treatments for Menopausal Symptoms
- Hormone Replacement Therapy
- Selective Estrogen Receptor Modulators
- Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine
Reuptake Inhibitors
- Gabapentin
- Other Treatments
Emerging Treatments for Menopausal Symptoms
- Wyeth' s Pristiq
- Wyeth' s Bazedoxifene/Conjugated Estrogen Combination
- Depomed' s Gabapentin
- Schering-Plough' s Esmirtazapine
Outlook for the Menopausal Symptom Market
Tables
- 1. Common Brands of Hormone Replacement Therapy
- 2. Common Selective Serotonin Reuptake Inhibitors and Serotonin and
Norepinephrine Reuptake Inhibitors
- 3. Emerging Agents for the Treatment of Menopausal Symptoms
- 4. Sales of Agents to Treat Menopausal Symptoms, 2008
Figures
- 1. Endocrine Changes Associated with Menopause
- 2. Worldwide Sales of Hormone Replacement Therapy, 2003-2008
|
